Clinical trial Recruiting at 1 site Observational Ages 18 and up

Evaluating cannabis extract for fibromyalgia symptoms

Official title: ObServational StUdy of CaNnabis ExtRact in FIbromyalgia SyndromE

Run by I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · NCT06747039 · Data updated 2026-11-12

This study is testing if a cannabis extract can help people with fibromyalgia feel less pain and improve their overall quality of life over 12 weeks.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment38 (estimated)
SponsorI.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Academic / other
Locations1 site (Milan, Milano)
StatusRecruiting
StartedDecember 5, 2024
Main results expectedSeptember 2025
Study endsDecember 2025
Registry record updatedDecember 24, 2024
Trial IDNCT06747039 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with a diagnosis of fibromyalgia who have not found relief from first- or second-line treatments.

Probably not a fit

Patients with fibromyalgia who are currently stable on other pain management therapies or those with psychiatric diagnoses may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effects of the cannabis extract Avextra 10/10 solution on pain, fatigue, sleep, and quality of life in patients diagnosed with fibromyalgia syndrome. Participants will complete surveys regarding their symptoms at baseline, and then again at 4, 8, and 12 weeks after starting the treatment. The primary focus is to determine if the cannabis extract can significantly reduce pain after 12 weeks of use. Secondary objectives include evaluating its impact on fatigue, sleep, anxiety, and depression over the same period.

Why it matters

Potential benefit: If successful, this study could provide a new treatment option for managing fibromyalgia symptoms, potentially improving patients' quality of life.

How similar studies have gone: While cannabis-based treatments for fibromyalgia are gaining attention, this specific approach using Avextra 10/10 is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with a diagnosis of FM according to 2016 American College of Rheumatology Criteria.
* Patients with FM prescribed cannabis extract Avextra 10/10 solution after failure and/or intolerance of first- or second-line treatment.
* Aged 18 years and older.
* Able to fully understand and fill questionnaires.
* Able to provide informed consent, according to requirements of local IRB/ethics committee.

Exclusion Criteria:

* Known history of pain not due to FM.
* Patients who have not received stable therapy for pain, sleep disorders, or any psychiatric condition for at least 2 weeks.
* Patients who are taking other types of medical cannabis besides Avextra 10/10 solution.
* Concomitant diagnosis of other pathologies that could interfere with clinical judgment.
* Psychiatric diagnosis according to DSM-V-TR
* Pregnancy or breastfeeding

Where it's running

  • IRCCS Ospedale Galeazzi-Sant'Ambrogio
    Milan, Milano, Italy
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.